Welcome to our dedicated page for Petmed Express news (Ticker: PETS), a resource for investors and traders seeking the latest updates and insights on Petmed Express stock.
PetMed Express, Inc. (PetMeds) (NASDAQ: PETS) generates a steady flow of corporate, financial, and operational news that is relevant to investors, analysts, and pet healthcare observers. As a national online pet pharmacy and parent company of PetCareRx, PetMeds regularly issues press releases and SEC reports covering its business performance, governance, regulatory status, and strategic developments.
News about PetMed Express often includes updates on its financial reporting, such as the filing of its Annual Report on Form 10-K and preliminary revenue information for fiscal quarters. The company has reported on investigations by its Audit Committee into accounting and control matters, the resulting restatement of certain prior financial statements, and the identification of material weaknesses in internal control over financial reporting. Related news items also cover notices from Nasdaq regarding delayed SEC filings and the company’s plans to regain compliance with listing requirements.
Corporate governance and leadership changes are another frequent news theme. PetMed Express has announced the resignation of senior executives, the appointment of an interim Chief Executive Officer and an interim principal financial officer, and the addition of independent directors with audit and financial expertise to its board. These updates provide insight into how the company is addressing oversight, financial governance, and board composition.
Strategic and transactional news includes unsolicited, non-binding acquisition proposals from investment firms such as SilverCape Investments Limited and Cardone Ventures, each expressing interest in acquiring all outstanding shares of PetMed Express at a specified cash price per share, subject to customary conditions. The company has also highlighted partnerships and initiatives in the pet healthcare community, such as fundraising efforts with the myBalto Foundation to support emergency veterinary care. Together, these news items offer a detailed view of PetMed Express’s evolving business, governance, and strategic landscape.
PetMed Express (NASDAQ: PETS) has scheduled its fiscal third quarter 2025 earnings conference call for Monday, February 10, 2025, at 4:30 PM Eastern Time. The company will release its financial results for the quarter ended December 31, 2024, prior to the call.
The earnings call will include a management presentation followed by a Q&A session. Investors can access the call through U.S. dial-in (877-407-0789) or international number (201-689-8562). A replay will be available until February 24, 2025, accessible via toll-free (844-512-2921) or international (412-317-6671) numbers with passcode 13750886.
PetMed Express, Inc., doing business as PetMeds and the parent company of PetCareRx, announced its participation in the 27th Annual ICR Conference, scheduled for January 13-15, 2025 in Orlando, FL.
Sandra Campos, Chief Executive Officer and President, and Robyn D’Elia, Chief Financial Officer, will represent the company and meet with investors. They are scheduled to present at approximately 11:00 a.m. Eastern Time on Monday, January 13, 2025.
A live webcast of the presentation will be available on the “Events & Presentations” section of PetMed’s investor relations website at https://investors.petmeds.com.
PetMeds (NASDAQ: PETS) has announced the adoption of a duration shareholder rights plan to protect shareholders' interests. The plan, effective immediately until December 2, 2025, was implemented in response to recent significant stock accumulations and concerns that shares don't reflect the company's inherent value. Under the plan, shareholders will receive one right per common stock share as of December 16, 2024. These rights become exercisable if an entity acquires 12.5% or more of outstanding shares without Board approval, allowing other shareholders to purchase additional shares at a 50% discount to market price.
PetMed Express (NASDAQ: PETS) has partnered with Ordergroove to enhance its subscription and membership capabilities. The collaboration aims to modernize PETS' Autoship program by implementing advanced platform features including prepaid subscriptions, self-service management, and personalized promotions. The partnership integrates product catalogs from both PetMeds and PetCareRx, creating a unified subscription membership experience. CEO Sandra Campos emphasized that this strategic move will support innovation while increasing customer satisfaction and retention. The implementation is expected to expand PETS' subscriber base and improve service accessibility while enabling faster market innovations.
PetMed Express, Inc., operating as PetMeds and parent company of PetCareRx (Nasdaq: PETS), will participate in the Sidoti Micro Cap Conference on November 13-14, 2024. The event will be held virtually. Sandra Campos, CEO and President, will present to investors at approximately 1:45 p.m. Eastern Time on Wednesday, November 13, 2024. A live webcast of the presentation will be available on the “Events & Presentations” section of PetMed’s investor relations website at https://investors.petmeds.com.
PetMed Express (NASDAQ: PETS) reported its Q2 fiscal 2025 financial results with net sales of $59.6 million and a gross margin of 29.1%, up 0.8% year-over-year. The company posted net income of $2.3 million, or $0.11 per diluted share, compared to $0.7 million, or $0.03 per diluted share, in the prior year period. Adjusted EBITDA reached $2.1 million, improving from a loss of $(1.5) million in Q1 fiscal 2025, though down from $3.4 million year-over-year. The company highlighted progress in its business transformation, including consolidation of operations and cost structure improvements.
PetMed Express (PETS) has announced its upcoming fiscal second quarter 2024 earnings conference call, scheduled for November 6, 2024, at 4:30 PM Eastern Time. The company will release its financial results for the quarter ended September 30, 2024, before the call. Management will host the call followed by a Q&A session. The call will be accessible via U.S. dial-in (877-407-0789) and international dial-in (201-689-8562). A replay will be available until November 20, 2024, through toll-free (844-512-2921) and international (412-317-6671) numbers with passcode 13748837.
PetMed Express, Inc. (Nasdaq: PETS) has appointed Robyn D'Elia as Chief Financial Officer, effective September 16, 2024. D'Elia brings over 25 years of experience in financial leadership and strategic planning, including 24 years at Bed Bath & Beyond where she served as CFO from 2018 to 2020. Most recently, she was CFO at Odeko, a privately held operations partner for independent coffee shops and cafes.
As CFO at PetMeds, D'Elia will oversee the entire finance organization and report directly to President and CEO Sandra Campos. The company expects her expertise in financial discipline, operational rigor, and scaling organizations to be valuable as they expand and aim to deliver long-term value for shareholders, customers, and employees.
PetMed Express (Nasdaq: PETS), parent company of PetCareRx, announces its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event is scheduled for September 4-6, 2024 in New York. Sandra Campos, CEO and President of PetMeds, will engage in a fireside chat on September 6, 2024, at 7:45 a.m. (Eastern Time).
Investors and interested parties can access a live audio webcast of the fireside chat through the 'Events & Presentations' section of PetMed's investor relations website. Following the event, a replay will be available for approximately 90 days on the same platform.
PetMed Express, Inc. (NASDAQ: PETS) reported its fiscal 2025 first quarter financial results. Net sales decreased by 13% to $68 million compared to the prior year quarter. However, the company achieved a net income of $3.8 million, or $0.18 diluted earnings per share, compared to a net loss in the previous year. This improvement was primarily due to a $8.7 million reversal of accumulated stock compensation expense associated with the former CEO's departure. The company's Adj. EBITDA was $(1.5) million, $4.9 million lower than the prior year quarter.
CEO Sandra Campos emphasized that Q1 FY'25 was a transition quarter, with new leadership focusing on cost reduction initiatives and customer growth strategies. The company is working on combining operations between PetMeds and PetCareRx, and early positive signs are validating their strategy to create an ecosystem of products and services for pets' well-being.